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Background: Depression is a common symptom in people with multiple sclerosis. We systematically reviewed
published controlled trials on the effectiveness of cognitive behavioural therapy (CBT) for the treatment of
depression in people with multiple sclerosis.
Methods: Publications were identified using MEDLINE, PsycINFO and the Cochrane Central Register of Controlled
Trials to June/July 2013. We combined thesaurus and free-text terms which were synonyms of the concepts
multiple sclerosis, depression and cognitive behavioural therapy. We included published controlled trials which
compared individual, group CBT, conducted face-to-face or remotely, to no CBT. Two reviewers extracted data to
calculate standardized mean differences (SMD) for self-reported symptoms of depression and weighted mean
differences (WMD) for the Multiple Sclerosis Impact Scale (MSIS-29), with 95% Confidence Intervals (CIs). We
investigated statistical heterogeneity using I2.
Results: Seven eligible studies (n = 433) were identified, which evaluated the effect on depression of CBT
delivered individually (3 studies), in a group (3 studies) and by computer (1 study). The summary effect (SMD -0.61,
95% CI -0.96 to -0.26, p=0.0006) was reduced (SMD -0.46, 95% CI -0.75 to -0.17, p=0.002) when an outlying study
was removed in a sensitivity analysis to examine statistical heterogeneity. Three studies (n=213) observed a
direction of effect using the MSIS-29 which was not statistically significant (WMD -4.36, 95% CI -9.33 to 0.62, p=0.09).
There was no between-subgroup heterogeneity (I2=0).
Conclusions: CBT can be an effective treatment for depression in MS. Further research should explore optimal
durations and modalities of treatment for patients with different characteristics.
Keywords: Cognitive-behavioural therapy, Depression, Multiple sclerosis, Quality of life, Systematic reviewBackground
Multiple Sclerosis (MS) is a chronic, immune-mediated
condition which affects the central nervous system. Ini-
tially, the disease usually involves repeated episodes of
symptoms including impaired vision, visual cognition or
balance, limb weakness, pain and fatigue. Permanent phys-
ical and cognitive disabilities often follow later [1]. Depres-
sion is a common co-morbidity in people with MS. Up to
50% of people with MS will experience major depressive
disorder in their lifetime [2], a figure considerably higher* Correspondence: d.hind@sheffield.ac.uk
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reproduction in any medium, provided the orthan that reported for either the general public or many
other chronic patient populations [3,4]. Depression in MS
has been associated with breakdowns in interpersonal
relationships and employment [5], cognitive impairment
[6,7], decreased medication adherence [8], heightened
suicide risk [9,10] and has been recognised as a major
determinant of patient quality of life [11-14]. A variety
of aetiologies have been proposed, collectively suggest-
ing a complex interrelationship between biological and
psychosocial factors [15-17].
Left untreated, depression in MS does not appear to
remit spontaneously [18], however evidence suggests
that it is amenable to treatment by both pharmacological
and psychotherapeutic interventions [19,20]. Cognitived. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by conferring skills to identify and reappraise negative
thoughts impacting on feelings and behaviours [21]. One
focus of CBT has been on the impact of maladaptive
coping styles on depression in MS [22]. The use of
emotion-focused coping styles has consistently been
related to more negative adjustment [23-25] and CBT
can be used to support the adoption of more beneficial
problem-focused coping styles [17]. CBT techniques can
also be applied to reduce perceived disease burden and
improve wellbeing [23,26,27].
Previous reviews suggest that CBT for depression has
demonstrated promising but inconclusive results in
people with MS [28,29]. Three relevant controlled trials
have been published since the last systematic review was
completed, including the largest study yet conducted on
the topic. These trials also use a recently validated
disease-specific quality of life instrument, which people
with MS report best reflects their concerns [30]. The
objective of this review is an up-to-date overview of
controlled trials, assessing the impact of CBT on patient-
reported measures of depression and disease-specific qual-
ity of life in people with MS. Reporting conforms to the
PRISMA statement [31]. A PRISMA checklist is provided
in Additional file 1.
Methods
Protocol and registration
The methods for this review were developed by members
of the team and piloted as part of a Masters in Public
Health dissertation written in 2008-9 (available on re-
quest). In 2009-10, the methods were adapted without
drafting or publishing a formal protocol (see Discussion)
and the review was completely repeated by the authors.
As initial data extraction was completed prior to the in-
ception of the PROSPERO database [32], the protocol
was not registered.
Eligibility criteria
Included studies had populations aged 18 years or over
with diagnoses of MS and depression, either as a psy-
chiatric diagnosis or at clinically important levels on a
validated depression scale. No restrictions were placed
on length of follow-up. Populations with co-morbid
dementia or other psychiatric disease unrelated to MS
were excluded.
The intervention in eligible studies was CBT delivered
by therapists or in a computerised online form. Therapist-
led CBT was delivered individually (face-to-face or by
telephone) or in groups. Studies evaluating neuropsycho-
logical training or cognitive rehabilitation programmes
were ineligible. Comparator groups were alternative talk-
ing therapies, waiting list controls, ‘standard care’ (however
defined) or no treatment for depression. In order to beincluded, studies had to evaluate self-reported symptoms
of depression using at least one validated instrument. Only
randomised and quasi-randomised controlled trials were
included. Studies not published in English were excluded.
Literature search
On 10th July 2013 we searched Ovid MEDLINE In-
Process & Other Non-Indexed Citations and Ovid
MEDLINE 1946 to Present, Ovid PsycINFO 1806 to July
Week 1 2013 and the Cochrane Central Register of
Controlled Trials: Issue 6 of 12, June 2013 for controlled
trials evaluating CBT for the treatment of depression in
people with MS. We used terms related to MS, depression
and CBT (see Additional file 2 for full search details for
each of the databases). We used Google to find home
pages of authors of included studies and screened these
for references not identified by the searches.
Study selection
Two researchers (AT and JC) independently screened titles
and abstracts for eligibility; differences were resolved by
discussion with DH.
Data extraction
AT and JC used a standardised data extraction form to
extract data on the study setting, design, participants
and descriptors of the intervention and control group
(content and duration of treatments). We abstracted
baseline prognostic characteristics, including age, sex,
duration and course of disease, MS-specific disability
measured by the Expanded Disability Status Scale or the
Guy’s Neurological Disability Scale [33,34] and self-
reported depression, however measured. We extracted
outcome data at baseline and follow-up, as reported in
the paper.
Quality assessment
AT and JC assessed the included studies, unblinded, for
generic dimensions of methodological quality associated
with estimates of treatment effects in controlled trials:
(1) concealment of the allocation schedule; (2) gener-
ation of the allocation sequences (randomization); and,
(3) inclusion in the analysis of all randomized participants
(intention-to-treat analysis), with all clinician withdrawals
or patient dropouts accounted for [35]. Disagreement be-
tween researchers about any aspect of data abstraction or
validity assessment was resolved by recourse to a third re-
viewer (DH). As the Cochrane Handbook recommends
that tests for funnel plot asymmetry should be used only
when there are at least 10 studies included in the meta-
analysis, we did not evaluate the potential for publication
bias [36]. We used the methods described by Dwan and
colleagues [37] to assess the presence of Outcome Report-
ing Bias (ORB). Contact with authors related only to
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As adequate outcome data on self-reported depression
was available for all studies, an ORBIT matrix was not
completed. We did not conduct sensitivity analysis to con-
sider robustness to either ORB or study publication bias
as the former was not detected, and insufficient studies
were retrieved to detect the latter.Synthesis
The primary outcome was self-reported symptoms of de-
pression measured on any validated instrument. The sec-
ondary outcome was the score on the Multiple Sclerosis
Impact Scale (MSIS-29) psychological subscale [38]. We
did not pre-specify a time point for assessment of any
outcomes, as we were aware of between-study variation
in this regard.
As studies assess self-reported symptoms of depression
using different scales we pooled estimates of clinical effect
using the standardised mean difference (SMD) in which
the size of the intervention effect is represented in units of
the standard deviations (SD). Negative SMDs indicate dif-
ferences in self-reported symptoms of depression which
favour the CBT arm. Conventionally, values of 0.20, 0.50,
and 0.80 indicate, respectively, small, medium, and large
effects [39]. Where non-reported outcome data could be
neither imputed nor recovered from the authors of the
original papers, the effect sizes were deemed not estim-
able. For MSIS-29 scores, non-standardised differences
were pooled; otherwise, the analysis strategy was the same
as previously.
The graphs in the results section present the number
randomised at all time points where an intention-to-
treat analysis was available, but the number analysed at
each time-point where an available case analysis was
available. Trials were combined using the DerSimonian
and Laird random effects model [40]. We used I2 to
measure the amount of between-study variation in effect
estimates which could not be explained by the play of
chance alone (statistical heterogeneity). Conventionally,
I2 values of 25%, 50%, and 75% denote low, moderate,
and high levels of inconsistency [41].
In the absence of direct comparisons, we used a test
for interaction to test the null hypothesis that there is no
difference between individual CBT and group CBT [42].Results
Searches and selection
After eliminating duplicates, 107 unique citations were
retrieved from the searches, of which 43 full papers were
included. We excluded 19 full papers, because of ineligible
populations (n=10), interventions (n=6), language (n=1),
and studies not being randomised controlled trials (n=2).
Seven discrete studies, represented by 24 citations due tomultiple publication, met the inclusion criteria (Figure 1,
Table 1).
Study characteristics
The studies were undertaken in the UK (n=3 [30,43,44]),
the US (n=3 [45-47]) and Australia (n=1 [48]), and were
published between 1984 and 2011. Only three studies
reported MS diagnostic criteria, two using the Poser cri-
teria [45,46], one the McDonald criteria [30]. Five stud-
ies recruited participants through local MS community
centres or outpatient clinics, advertising through MS
newsletters and referral from clinical staff specialising
in MS [30,43,44,46,48]. Three studies recruited through
a medical care program database [30,45,47].
Population characteristics
The average age of study participants ranged from around
42 [48] to 48 [47] years (Table 2). The average number of
years participants had lived with MS varied and was re-
ported inconsistently across studies. Two studies did not
report the MS type [47,48]; relapsing remitting was the
most common type in other studies with primary progres-
sive disease only represented in two studies [43,44]. All
but one study reported the level of MS-related disability:
[48] four studies reported Guy’s Neurological Disability
Scale averages ranging from about 18 to about 23; two
studies reported Expanded Disability Status Scale averages
ranging from 2.4 to about 4. In each of five trials
[30,44,46-48] who used the BDI, the median scores at
baseline were in the moderate range (19-29 points), with
two trials [47,48] probably recruiting a significant minority
in the more severe range.
Four trial reports included data about study take-up
[30,43,44,47]. A median of 45% (range 12% [30] to 71%
[44]) of those approached about the study screened eli-
gible (with the remainder in some studies refusing as well
as failing screening). Medians of 18% (range 4% [30] to
49% [44]) of those approached and 50% (range 26% [43] to
85% [47]) of those screening eligible entered the trial.
Intervention characteristics
In three trials, the intervention was delivered by an indi-
vidual therapist, face-to-face in one trial [46], and by tele-
phone in two trials [45,47]. Three trials evaluated group
therapy programmes, in which patients were randomised
into groups consisting of 4-10 individuals [43,44,48]. One
trial evaluated computerised CBT (cCBT) [30]. The dur-
ation of the intervention ranged from 6-16 weeks (median
8 weeks) with study follow-up period ranging from 4-64
weeks after randomisation or the initiation of treatment.
The majority of the studies reported weekly sessions, but
two studies evaluated fortnightly therapy given over 12
weeks [43,44]. The duration of therapy sessions ranged
from 50-120 (median 50) minutes. CBT interventions
# of records after dupicates
removed
n = 107
# of records screened
n = 91 # records excluded
n = 64
# of full-text articles assessed for
eligibility
n = 43
# of full - text articles excluded, with
reasons
n = 19
Not multiple sclerosis n=10
Not CBT n=6
Not controlled trials n=2
Not English language n=1
# of studies included in qualitative
synthesis
n=7:
Larcombe et al 1984
Mohr et al 2000
Mohr et al 2001 (8 citations)
Mohr et al 2005 (9 citations)
Forman et al 2010
Lincoln et al 2011 (3 citations)
Cooper et al 2011
# of records identified through
database searching
n=152
# of additional records identified
through other sources
n=1
Id
en
tif
ic
a
tio
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
u
de
d
# of studies included in
quantitative synthesis (meta -
analysis)
n=7
Figure 1 Study flow (PRISMA) diagram.
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positive behaviours, social interaction, and training to
identify and challenge cognitive distortions. Details re-
garding the composition of individual sessions were
generally limited. Five studies stated that a manual was
used to guide treatment [43-47]. Patients were provided
with a workbook to act as a visual aid in delivering
treatment in the two studies that used telephone admin-
istered CBT [45,47]. Five studies used CBT interventions
that incorporated specific skills for managing common
MS related issues including fatigue, pain and stress
[43-47]. Additional relaxation techniques were also incor-
porated in two studies [43,44]. The cCBT interventionconsisted of a generic, commercial, interactive, web-based
CBT package ‘Beating the Blues’ , which had not been
adapted to deal with the symptoms of MS [30]. Home-
work was set in six studies [30,43-45,47,48].
Of the six studies that included contact with a therap-
ist, three used only a single therapist to deliver treat-
ment to all patients randomised to CBT [43,44,48]. Two
studies used more than one doctoral level psychologist
with between 1-9 years postdoctoral clinical experience
[46,47]. Two studies used advanced postgraduate-level
researchers with several years’ experience in providing
psychotherapy and prior treatment for MS patients
[45,48]. Two studies used assistant psychologists to
Table 1 Study characteristics
Study Population Intervention Comparator(s) Outcomes (Primary,
Secondary)
Larcombe
(1984) [48]
BDI ≥ 20; Self-reported depression ≥ 3 months;
Met Feighner criteria for ‘definite’ or ‘probable’
depression; No psychological co-morbidities;
Low suicide risk; Normal memory function; No
concurrent or prior treatment with major
tranquilisers or lithium. Diagnosis of MS
confirmed by a neurologist
Six weekly 90 minute group
cognitive behavioural therapy
sessions
Waiting list
for delayed
treatment
BDI; HRSD; Mood Ratings (3 item
questionnaire, 10 point scale);
Depression as rated by significant
other (6 item questionnaire,
4 point scale)
Mohr
(2001) [25]
BDI ≥ 16; HRSD ≥ 16; Clinical diagnosis of MDD
assessed using SCID; No psychological or
neurological co-morbidities, suicidal tendencies
or CNS disorders; Willingness to abstain from
any other treatment for depression than that
provided in the study. Confirmed diagnosis of
MS (Poser criteria)
Sixteen weekly 50 minute
individually administered cognitive
behavioural therapy sessions
Supportive-
expressive group
therapy;
Sertraline
BDI; BDI-18; HRSD; MDD assessed
using SCID
Mohr
(2005) [47]
BDI-II ≥ 16; HRSD ≥ 14; GNDS ≥ 3 on one or
more areas of functioning; No co-morbid
dementia, psychosis, substance abuse or
suicidal tendencies; Not currently undergoing
psychotherapy; No medication other than
antidepressants. Diagnosis of MS confirmed
by a neurologist
Sixteen weekly 50 minute
telephone administered cognitive
behavioural therapy sessions
Telephone
administered
supportive
emotion-focused
therapy
BDI-II; HRSD; MDD assessed using
SCID; Positive affect measured
using PANAS-PA
Mohr
(2000) [45]
POMS-DS ≥ 15; If in treatment for depression
must have been in that treatment for ≥ 3
months; No co-morbid dementia or
neurological disorders. Confirmed diagnosis
of MS (Poser criteria)
Eight weekly 50 minute telephone
administered cognitive
behavioural therapy sessions
Standard care POMS-DS; Post-treatment
adherence to IFNβ-1a
Forman
(2010) [43]
Diagnosis of MS > 3 months; HADS ≥ 8 or
GHQ-12 ≥ 3
Six fortnightly 120 minute group
therapy sessions based on
cognitive-behavioural and
psycho-educational framework
Standard care HADS; GHQ-12; MSIS; MSSE;
SF-36
Lincoln
(2011) [44]
Diagnosis of MS > 12 months; HADS ≥ 8 or
GHQ-12 ≥ 3. Diagnosis of MS confirmed by
a neurologist
Six fortnightly 120 minute group
therapy sessions based on
cognitive-behavioural and
psycho-educational framework
Standard care BDI-II; HADS; GHQ-12; MSIS;
MSSE; EQ-5D
Cooper
(2011) [30]
BDI-II ≥ 14 but < 29; EDSS < 8.5; MMSE < 24;
No psychological co-morbidities; Low suicide
risk; No treatment from psychologist,
psychotherapist or psychiatrist within last
3 months. Confirmed diagnosis of MS
(McDonald criteria)
Eight 50 minute computerised
cognitive behavioural therapy
sessions
Standard care BDI-II; MSIS; SF-36; PHQ-9; GAD-7
BDI: Beck Depression Inventory; EDSS: Expanded Disability Status Scale; GAD-7: Generalised Anxiety Disorder 7-item; GHQ-12: General Health Questionnaire
12-item; GNDS: Guy’s Neurological Disability Scale; HADS: Hospital Anxiety and Depression Scale; HRSD: Hamilton Rating Scale for Depression; MDD: Major
Depressive Disorder; MMSE: Mini Mental State Examination; MSIS: Multiple Sclerosis Impact Scale; MSSE: Multiple Sclerosis Self-Efficacy Scale; PANAS-PA: Positive
Affect subscale of the Positive and Negative Affect Scale; PHQ-9: Patient Health Questionnaire 9-item; POMS-DS: Profile of Mood States - Depression-Dejection
Scale; SCID: Structured Clinical Interview for DSM-IV; SF-36: Short Form Health Survey.
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fidelity was assessed in two studies using a modified
version of the Cognitive Therapy Scale, [46,47] while
adherence was informally monitored in one study
through review of audio-taped treatment sessions [45].
Three studies did not report attempts to monitor therapist
treatment adherence [43,44,48]. In all six therapist-led
studies, those delivering the intervention received regular
supervision by a senior and experienced clinician. No
study reported attempts to monitor the receipt or enact-
ment of CBT techniques by intervention arm participants.
In the six studies where data was available, [30,43,45-48]
a median of 9% (range 5% [47] to 31% [45]) of thoserandomised to CBT interventions failed to complete
their course.
Comparator characteristics
Two included studies used ‘active’ comparators, one in-
corporating a group therapy and a pharmacotherapy arm
(which was not used in the meta-analysis below) [46] and
one including a telephone-administered psychotherapy
comparator arm [47]. Four studies randomised partici-
pants to “standard care” control conditions. Of these, two
studies restricted access to any other psychotherapeutic
interventions for the duration of the trial, [43,45] while
two studies did not restrict this treatment in any way
Table 2 Participant baseline characteristics
Study Mean age (SD) Sex Mean (SD) MS
duration in years
MS disease course EDSS/GNDS
mean (SD)
Depression severity
measure mean score (SD)
Larcombe
(1984) [48]
42.5 (NR) CBT: F7 M2;
Ctrl: F6 M4
NR NR NR BDI. CBT: 27.44 (5.64);
Ctrl: 29.00 (8.67)
Mohr
(2001) [25]
43.9 (10.0) F46 M17 7.7 (NR) RR or SP EDSS: 2.4 (NR) BDI. CBT: 24.8 (7.1);
Ctrl: 23.5 (7.6)
Mohr
(2005) [47]
CBT: 48.6 (9.6);
Ctrl: 47.3 (10.1).
CBT: F47 M15;
Ctrl: F51 M14
CBT: 11.6 (10.1);
Ctrl: 10.9 (10.1)
NR GNDS. CBT: 23.9 (5.8);
Ctrl 22.9 (6.7)
BDI. CBT: 27.00 (7.78);
Ctrl: 28.32 (7.91)
Mohr
(2000) [45]
CBT: 42.6 (12.8);
Ctrl: 42.1 (9.4)
CBT: F10 M6;
Ctrl: F13 M3
CBT: 6.1 (6.6);
Ctrl: 6.1 (6.7)
CBT: RR16; Ctrl: RR16 GNDS. CBT: 19.0 (9.2);
Ctrl: 17.9 (9.2)
POMS-DS. CBT: 33.1
(12.4); Ctrl: 27.9 (12.1)
Forman
(2010) [43]
CBT: 47.3 (10.3);
Ctrl: 47.7 (9.8)
CBT: F16 M4;
Ctrl: F16 M4
CBT: 7.3 (5.4);
Ctrl: 12.4 (11.4)
CBT: RR13 PP3 SP3 B1;
Ctrl: RR13 PP1 SP6
GNDS. CBT: 19.39
(5.55); Ctrl: 25.37 (8.04)
HADS-D. CBT: 9.5 (3.3);
Ctrl: 8.5 (4.3)
Lincoln
(2011) [44]
CBT: 44.5 (11.1);
Ctrl: 47.5 (10.5)
NR CBT: 9.2 (7.8);
Ctrl: 10.5 (8.0)
CBT: RR55 PP4 SP12 B1;
Ctrl: RR48 PP11 SP18 B2
GNDS. CBT: 17.3 (7.8);
Ctrl: 16.7 (6.9)
BDI. CBT: 23.1 (12.2);
Ctrl: 21.9 (8.7)
Cooper
(2011) [30]
CBT: 48 (7.7);
Ctrl: 42 (7.0)
CBT: F11 M1;
Ctrl: F7 M5
NR CBT: RR7 SP5; Ctrl: RR12 EDSS. CBT: 4.8 (1.7);
Ctrl: 3.6 (1.8)
BDI. CBT: 21.0 (4.0);
Ctrl: 23.3 (5.2)
B: Benign MS disease course; BDI: Beck Depression Inventory; CBT: Cognitive Behavioural Therapy group; Ctrl: Control group; EDSS: Expanded Disability Status
Scale; F: Female; GNDS: Guy’s Neurological Disability Scale; HADS-D: Hospital Anxiety and Depression Scale – Depression subscale; M: Male; NR: Not reported;
POMS-DS: Profile of Mood States - Depression-Dejection Scale; PP: Primary-progressive MS disease course; RR: Relapsing-remitting MS disease course;
SP: Secondary-progressive MS disease course.
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[48]. The studies differed in the extent to which they per-
mitted participants to continue with additional therapy
outside of that provided in the trial. One study excluded
patients who were unwilling to abstain from psychological
or pharmacological treatment for depression other than
that provided in the study during the treatment period
[46]. One study did not permit participants to receive any
additional psychotherapy, though 55% of the sample was
concurrently using antidepressants [47]. In one of the
studies by Mohr and colleagues two patients randomised
to CBT received either antidepressant medication or psy-
chotherapy [45]. Cooper and colleagues reported that,
within the CBT arm, one patient received additional psy-
chotherapy, while seven patients used antidepressants
[30]. The study by Larcombe and Wilson reported one pa-
tient in the CBT arm and two participants in the waiting
list control received additional antidepressant medication
[48]. Two studies did not report additional treatment re-
ceived by participants during the study period [43,44].
Quality assessment
The quality of the studies, outlined in Table 3 was variable.
Only two studies clearly demonstrated adequate conceal-
ment of the allocation schedule [30,44]. Two studies with
small sample sizes used block randomisation in such a
way that made the randomisation of later blocks predict-
able thus undermining allocation concealment and open-
ing the study up to selection bias [43,46]. One study
reported a quasi-random method of block randomisation
generally thought to be inadequate [46]. The median loss-
to-follow-up at the time of the primary outcome assess-
ment (made at between 7 and 16 weeks) was 8% (range
4% [47] to 28% [45]); studies that followed up for longer,reported greater attrition at subsequent time-points. Two
studies did not perform intention-to-treat analysis, having
lost one and two participants to follow-up respectively
[43,48]; in each of the other five studies [30,44-47], the
use of “last observation carried forward” was necessary
to impute continuous data missing at follow-up. Sample
sizes ranged from 32 to 122 (median 45) for individual
CBT studies and from 20 to 151 (median 38) for group
CBT studies. The one cCBT study had a sample size of 24.
The risk of ORB was deemed low. No study was ex-
cluded because authors failed to use a validated depression
inventory (primary outcome). Included studies which did
not use the MSIS-29 all commenced prior to published
work on its validation [38,49].
Synthesis
We used Review Manager 5.1 to meta-analyse study out-
comes. In the forest plots (Figures 2, 3, 4 and 5), the first
author and publication date is followed by the duration of
therapy in weeks and the timing of follow-up expressed as
the number of weeks since randomisation. The Larcombe
and Forman teams presented available case analyses, and
the denominators for these studies in graphs express the
number analysed, rather than the number randomised
[43,48]. All 7 studies reported mean (SD) post-scores.
Seven studies (n = 433) compared between 6 and 16
weeks of individual, group or computerised CBT to no
CBT (Figure 2). Studies employed summary scores from
different inventories measuring symptoms of self-reported
depression: BDI; [46,48] BDI-II; [30,44,47] POMS-DS; [45]
HADS-D [43]. At end of treatment, CBT of any type and
duration conferred an average difference in self-reported
symptoms of depression of 0.6 SD (SMD -0.61, 95% CI
-0.96 to -0.26, p=0.0006). High levels of statistical
Table 3 Quality assessment
First author Allocation concealment Randomisation Blinding Intention to treat (ITT) and withdrawals Attrition at primary outcome
timepoint
Largest number
lost to follow-up
Larcombe
(1984) [48]
Australia
Unclear Unclear Raters for HRSD were
blind to experimental
conditions and
assessment occasions
1/20 (5%) withdrew (1 CBT). Participant
discontinued treatment after one session.
No ITT analysis
1/20 (5%) at 7 weeks (1 CBT) 1/20 (5%) did not
complete 7 week
outcome assessment
(1 CBT)
Mohr (2001)
[25] USA
Inadequate Inadequate: Quasi-random,
block randomisation
None 11/63 (18%) dropped out of treatment
(1 CBT, 4 Group therapy, 6 Sertraline). ITT
analysis carried out on all subjects
9/63 (14%) at 16 weeks
(3 SEG, 6 Sertraline)
9/63 (14%) did not
complete 16 week
outcome assessment
(3 SEG, 6 Sertraline)
Mohr (2005)
[47] USA
Unclear Unclear: Stratified based
on whether patient
currently diagnosed as
having MDD and using
antidepressant medication
All interviewers
conducting telephone
assessments were
blinded to treatment
allocation
7/127 (6%) did not complete the
16 weeks of therapy (3 CBT, 4 Control).
6 participants dropped out by their own
choice, 1 was removed from the trial due
to an irrelevant issue. ITT analysis carried
out on all subjects
5/127 (4%) at 16 weeks
(2 CBT, 3 Control)
15/127 (12%) did
not complete
28 week follow-up
(6 CBT, 9 Control)
Mohr (2000)
[45] USA
Unclear Unclear None 5/32 (16%) dropped out of treatment
(5 CBT). CBT: Inability to make phone
appointments or reported conflicts with
other obligations. ITT analysis carried out
on all subjects using last observation
carried forward for missing data
9/32 (28%) at 8 weeks (5 CBT,
4 Control). Control: 3 declined
final assessment, 1 died (medical
problem unrelated to MS)
9/32 (28%) did not
complete 8 week
outcome assessment
(5 CBT, 4 Control)
Forman (2010)
[43] UK
Inadequate: Independent
researcher held allocation
schedule. Small sample
made later groups
predictable
Adequate: Block
randomisation,
computer-generated
list of random numbers
Single blind. Outcome
questionnaires scored
and entered onto
computer by an
independent
researcher
7/20 (35%) randomised to group CBT
intervention did not attend the group
sessions. No ITT analysis
2/40 (5%) at 12 weeks (1 CBT, 1
Control). CBT: Did not return due
to bereavement. Control: Did not
return due to MS relapse
3/40 (7.5%) did not
complete 26 week
follow-up (2 CBT,
1 Control)
Lincoln (2011)
[44] UK
Adequate: Web-based
randomisation system
Adequate: Block
randomisation,
computer-generated
Data scored and
entered onto database
by researcher blind to
treatment allocation
1/151 subject withdrew (1 Control) shortly
after randomisation. ITT analysis carried out
on all subjects using last observation
carried forward for missing data
20/151 (13%) at 16 weeks (11 CBT,
9 Control). CBT: 2 patients were too
ill, 9 failed to return outcome
assessment. Control: 1 patient
withdrew, 1 was too ill, 7 failed to
return outcome assessment
24/151 (16%) did
not complete 32
week follow-up
(14 CBT, 10 Control)
Cooper (2011)
[30] UK
Adequate: Web-based
randomisation system
Adequate:
Computer-generated
Statisticians and PI
remained blind to
treatment allocation
codes until after the
final analysis
1/12 (8%) randomised to computerised CBT
formally requested discontinuation of
treatment citing time and lack of
enthusiasm as reasons. ITT analysis carried
out on all subjects using last observation
carried forward for missing data
3/24 (12.5%) at 8 weeks (3 CBT) 6/24 (25%) did not
complete 21 week
follow-up (2 CBT,
4 Control)
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Figure 2 Depression: post-treatment scores. Note: All forest plots used display available case analyses for the Larcombe and Forman studies,
but intention-to-treat analyses for other studies. See Table 3 for numbers lost to follow up at the post-treatment assessment.
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http://www.biomedcentral.com/1471-244X/14/5heterogeneity (I2 = 60%) suggest this result should be
interpreted with caution, but this appeared to be driven
by a single ‘outlier’ study [48]. When this study was re-
moved in a post hoc sensitivity analysis, all between-
study variation could be explained by the play of chance
alone (I2 = 0%) and the clinical effect size was reduced
(SMD -0.46, 95% CI -0.75 to -0.17, p=0.002). There was
no between-subgroup heterogeneity for the main analysis
(I2 = 0%), with or without this study included.
In the individual therapy subgroup, three studies
(n = 201) compared between 8 and 16 weeks of CBT to
no CBT. At end of treatment, CBT conferred an average
improvement in self-reported symptoms of depression of
0.4 SD (SMD -0.41, 95% CI -0.69 to -0.13). There was no
statistical heterogeneity within this subgroup.
In the group therapy subgroup, three studies (n = 208)
compared between 6 and 12 weeks of CBT to no CBT.
At end of treatment, CBT conferred an average improve-
ment in self-reported symptoms of depression of 1.0 SD
(SMD -1.00, 95% CI -2.00 to 0.01). There were high levels
of heterogeneity (I2 =85%); removal of the Larcombe study
from the analysis [48], discussed above, eliminated statis-
tical heterogeneity in the subgroup, but reduced the clin-
ical effect size to 0.5 SD (SMD -0.46, 95% -0.75 to -0.17).Figure 3 MSIS psychological subscale: post-treatment scores.Possible interpretations of the observed statistical hetero-
geneity are discussed below.
The one remaining study (n=24) investigated 8 weeks of
cCBT to standard care, reporting a difference of 0.8 SD
(SMD -0.85, 95% CI -1.69 to -0.00).
An indirect comparison of individual vs. group CBT
was undertaken by comparing the pooled mean differences
for individual therapy and group therapy. The comparison
gave a standardised mean difference of 0.59 (95% CI: -0.45
to 1.63; p=0.27) when including all 6 studies, or 0.05 (95%
CI: -0.35 to 0.45; p=0.81) when removing the outlying study.
We conclude that there is not enough evidence to suggest a
difference exists between these individual and group CBT
for the treatment of depression in people with MS.
Summary scores at end of treatment were available for
the MSIS psychological subscale from three studies (n=213,
Figure 3), which compared between 8 and 12 weeks of
CBT to no CBT. At end of treatment, CBT conferred an
advantage in self-reported MS-specific psychological symp-
toms of 4 points (WMD -4.36, 95% CI -9.33 to 0.62,
p=0.09). This effect translates to a change of 0.23 standard
deviations (SMD -0.23, 95% CI -0.50 to 0.04, p=0.09). There
was no statistical heterogeneity in either of these analyses
(I2 =0).
Figure 4 Depression: long-term follow-up assessments.
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tent, duration and follow-up times we did not consider
it appropriate to undertake a statistical synthesis of a
longer follow-up period for either self-reported symp-
toms of depression or the MSIS psychological subscale.
The outcome assessments made at various follow-up
times within the individual studies are presented in
Figures 4 and 5.
Discussion
Principal findings
When treating depression in people with multiple scler-
osis, CBT appears to confer a medium treatment effect
(0.5 SD) compared with standard care and some alterna-
tive psychotherapeutic interventions. In the small number
of studies where data was provided, CBT also improved
disease-specific quality of life in comparison to standard
care.Figure 5 MSIS psychological subscale: long-term follow-up assessmenStudy limitations
The methods for this review were based those developed
by the team and used in a Masters dissertation (available
on request); the research question and inclusion criteria
were established before the conduct of the review – a
criterion of the AMSTAR tool, used to assess the quality
of systematic reviews [50]. Initial data extraction was
completed before the development of the PROSPERO
database [32]. As the Cochrane Handbook notes, early
publication of a protocol for a review prior to knowledge
of the available studies reduces the impact of review
authors’ biases and allows peer review of the planned
methods [36]. Two departures from the original methods
did occur in this review. The assessment of outcome
reporting bias was undertaken because became best prac-
tice, while the review was ongoing [51]. The use of
CINAHL, EMBASE and grey literature searching were
also abandoned, due to resource constraints and becausets.
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http://www.biomedcentral.com/1471-244X/14/5none had produced unique references in the pilot work.
Searching Medline and specialised databases only, along
with checking reference lists and contacting experts, can
be justified under resource constraints in some topic areas
[52]. MEDLINE identifies 97% of all RCTs of cognitive
therapy for depression [53], whereas CINAHL in particu-
lar, rarely retrieves unique references for most topic areas
[54]. For these reasons, we believe the risk of bias associ-
ated with our search strategy is low.
Moderate to high levels of statistical heterogeneity, to-
gether with the low number of studies and the risk of bias
resulting from participant attrition mean these results
should be interpreted with caution. Statistical heterogen-
eity in the meta-analysis indicates that there are under-
lying clinical and methodological differences (variations in
populations, interventions and outcome assessments) be-
tween the studies. Much of the heterogeneity could be at-
tributed to a single small study which reported a very
large effect [48]. Formal meta-regression was not under-
taken but several differences between the Larcombe study
[48] and the other group therapy studies may explain the
disparity in effect sizes. The Larcombe study [48], con-
ducted in Australia was published twenty-five years prior
to Forman [43] or Lincoln [44], both conducted in the
UK. Larcombe [48] had higher mean baseline scores on
the BDI than the large Lincoln study [44] (Table 2; no
comparable data for Forman [43]). There was proportion-
ately higher levels of dropout in the large Lincoln trial
(n=151) [44], which provided the majority of the weight
for this subgroup, than the smaller Larcombe trial (n=20)
[48] (Figure 2; Table 3). Clinical effect sizes in psycho-
therapy trials tend to be significantly smaller in studies
with a sample size of greater than 50 or intention-to-
treat analyses (Lincoln [44]) than in smaller studies or
those with available case analyses (Larcombe [48] and
Forman [43,55]). This aside, the results are arguably
more consistent than may have been expected from
such diverse settings and protocols. Nevertheless, with
so few studies the estimate of heterogeneity will neces-
sarily be imprecise; for instance, although individual
CBT versus control had an estimated I2 of zero, its
upper 95% confidence limit was 77%. Exploration of the
impact of factors on effect sizes via meta-regression was
not undertaken due to the multitude of potential explana-
tory factors, limited data and a lack of standardisation in
reporting of primary research studies.
The pre-specified ineligibility of non-English language
studies resulted in the exclusion of one Persian language
study at the full paper stage. As far as we can tell from
the English abstract, this paper was not assessing self-
reported depression using a validated inventory, focusing
rather on a concept described as “hope of life”. It is un-
likely the exclusion of this study increases the risk of
bias in our own: there is no evidence that the use oflanguage restrictions in systematic review-based meta-
analyses causes systematic bias, although it can reduce
the precision of pooled estimates [56].
Key messages for patients, therapists, policy-makers
CBT may provide modest benefits in the treatment of de-
pression in some people with MS and can be provided
alongside or as an alternative to pharmacological interven-
tions. The meta-analysis suggests that delivery modes
other than traditional, one-to-one, face-to-face, therapist-
led CBT may be effective but, although remote delivery
can provide greater patient accessibility it also presents
certain challenges. In telephone-administration, the lack of
visual cues and non-verbal communication require add-
itional paperwork and experienced clinicians to facilitate
interaction effectively [45]. Patients have reported finding
cCBT physically burdensome, insufficiently supported for
proper application of the CBT model and exacerbating
feelings of social isolation [57].
Where reporting was adequate, the review highlighted
poor consent rates in some trials, which may reflect the
perceived attractiveness of CBT interventions as well as
of the research protocol. Whilst adherence to treatment
was generally good (higher than 90% completion) drop
out from one group [43] and one telephone CBT [45]
intervention exceeded the average dropout from psycho-
therapy of 22% cited elsewhere [58] by some margin.
Where researchers provided an explanation for poor take
up or adherence, it focused on patients prioritising therapy
over other commitments at the available times [43,45].
Whilst this could be framed in terms of resource-limited
services failing to offer flexibility and choice, it could also
indicate a low value placed on talking therapies by the
target client group.
Levels of self-reported depression were relatively low in
the trial populations, with all averaging within the moder-
ate range (20-28) on the BDI. Researchers who consider
the use of somatic symptoms common to MS in depres-
sion inventories as potentially flawed may also consider
the burden of affective symptoms reported by the trial
populations to be exaggerated [59,60]. This is relevant be-
cause the response to medication in those with moderate
depression is often quite poor. A meta-analysis of data
submitted to the Food and Drug Administration found
“virtually no difference” in treatment effect between
people with moderate levels of initial depression receiving
antidepressants or placebo [61]. It is also important to
note that the majority of patients included in these trials
had been diagnosed with MS for many years. The causes
of depression at this time are likely to differ from those in
the early years following diagnosis when patients are at
the greatest risk of suicide [62,63].
The effect size of 0.5 SD, which equates to between 3-
4 points on the BDI, is similar to that observed at
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comparing antidepressants with placebo for the treatment
of depression in physically ill people [64]. Modest treat-
ment effects, together with the comparably high costs of
staffing a clinical service may mean that bespoke CBT
interventions for people with MS may not be considered
cost-effective at conventional thresholds. One economic
analysis, which identified a 38% chance of relapse with
psychotherapy compared to 55% chance with pharma-
cotherapy alone, was unable to conclude face-to-face,
therapist-led CBT would be cost-effective in those with
moderate depression [65]. The growing availability in
some countries of low-intensity telephone CBT [66] and
the drive to manage a range of MS symptoms, including
fatigue, through nurse-led group CBT interventions [67,68]
may mean that services are available for those who wish to
access them.
Need for further research
There are a number of methodological limitations in the
current studies that should be addressed in future
research. The studies in our meta-analysis are small
(mean n=62) compared to those in other meta-analyses
on depression in physically ill people. The external
validity of the studies is likely to be limited, with only a
small number of therapists delivering the intervention
in each. To improve the generalisability of findings,
larger multi-centre trials are needed to ensure adequate
patient recruitment in addition to the use of a wider num-
ber of therapists. Future trials must include follow-up
periods of at least one year to examine the longer-term
effectiveness of CBT interventions, along with the poten-
tial for further booster sessions if necessary. Studies should
be designed with active comparators, such as supported
self-management or a variant of behavioural activation.
More studies incorporating drug comparator arms are
required. Only one of the studies in this review compared
the use of CBT to a pharmacological intervention [46].
The result that antidepressant medication and CBT show
comparable levels of effectiveness in mild to moderately
depressed individuals is not exclusive to MS patients [58].
Systematic reviews suggest that the combination of CBT
and antidepressant medication may be the most effective
mode of treatment for depression, without taking con-
comitant physical illness into account [69,70]. While the
Goldman Consensus statement on depression in multiple
sclerosis also favours combination therapy [20], their rec-
ommendation is not currently underpinned by controlled
trials involving people with multiple sclerosis.
There is a need for greater emphasis on disease-specific
quality of life outcome measures to be recorded in con-
junction with measures of depression severity. These
provide an indicator of how depression and disability
impact on the daily lives of people with MS moreeffectively than self-reported depression instrument scores
alone. The MSIS in particular has received support as a
useful patient-reported outcome measure from patients,
clinicians and researchers [30,57,71].
A large proportion of patients showed no improvement
in depressive symptoms, therefore a potentially important
direction for further research could be to establish what
individual characteristics or physical disease markers sig-
nal that a patient may be particularly suited to a particular
treatment such as CBT. Some work in this area has begun
to emerge, identifying baseline factors associated with
treatment response including patient social support [72]
and measures of neuropsychological functioning [73]. No
study has yet evaluated either the cost-effectiveness of
different durations or intensities of CBT programmes.
One study has compared the cost-effectiveness of group
CBT to standard care, concluding that there were statis-
tically significant differences in the average costs of care
favouring CBT [74]. The authors presented incremental
cost-effectiveness ratios using cost per point reduction
on the BDI-II (£118), rather than employing quality-
adjusted life years, favoured by health care commissioners.
Future research needs to account for the varying needs of
different patients and investigate whether a tailored
approach to CBT delivery is possible, which balances
value for money with patient acceptability.
Conclusions
CBT can be an effective intervention for reducing moder-
ate depression, over the short-term, in patients with MS.
Early evidence suggests this may also improve patient
quality of life. Further research is needed to evaluate
longer-term maintenance and the cost-effectiveness of this
intervention within this population.
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